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ABSTRACT
The hydrochlorothiazide (HCT) low solubility and permeability give rise to limited and variable bioavail-
ability; its low stability makes it difficult to develop stable aqueous liquid formulations; its low dose
makes the achievement of a homogeneous drug distribution very difficult. Thus, the aim of this study
was to investigate the effectiveness of a strategy based on the development of nanostructured lipid
carriers (NLC) as an innovative oral pediatric formulation of HCT with improved therapeutic efficacy.
The performance of various synthetic and natural liquid lipids was examined and two different prepar-
ation methods were employed, i.e. homogenization-ultrasonication (HU) and microemulsion (ME), in
order to evaluate their influence on the NLC properties in terms of size, polydispersity index, f-poten-
tial, entrapment efficiency, gastric stability, and drug release properties. PrecirolVR ATO5 was used as
solid lipid and TweenVR 80 and PluronicVR F68 as surfactants, formerly selected in a previous study
focused on the development of HCT-solid lipid nanoparticles (SLNs). The presence of PluronicVR F68 did
not allow ME formation. On the contrary, using TweenVR 80, the ME method enabled a higher entrap-
ment efficiency than the HU. Regardless of the preparation method, NLCs exhibited great entrapment
efficiency values clearly higher than previous SLNs. Moreover, NLC-ME formulations provided a pro-
longed release, which lasted for 6 h. In particular, NLC-ME containing TweenVR 20 as Co-Surfactant
showed the best performances, giving rise to a complete drug release, never achieved with previous
SLN formulations, despite their successful results. In vivo studies on rats confirmed these results, dis-
playing their best diuretic profile. Moreover, all HCT-loaded NLC formulations showed higher stability
than the corresponding SLNs.
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Introduction
Children are a special category of patients. The lack of suit-
able specific pediatric formulations often leads to the use of
extemporaneous preparations obtained starting from the
dosage form for adults, by dilution of liquid formulations,
opening or capsules or finely grinding of tablets, adminis-
tered as suspensions. However, such manipulations give rise
to a series of disadvantages, including in particular minor
dosing accuracy, unknown and variable bioavailability, poor
compliance for both children and caregivers, and lack of
data about the preparation stability (Pandolfini & Bonati,
2005; Standing & Tuleu, 2005).
Cardiovascular drugs are widely utilized for galenic pediat-
ric preparations in the hospital pharmacies, owing to their
use for a series of clinical conditions, such as heart failure,
hypertension, hypovolemic shock or edema (Associazione
Ospedali Pediatrici Italiani, 2005). Among these, diuretic
drugs such as hydrochlorothiazide (HCT), are often used in
the management of hypertension. Owing to its low solubility
and permeability (Basant Kumar Reddy & Karunakar, 2011),
HCT is ranked as a BCS class IV drug (Amidon et al., 1995),
and presents problems of poor and variable bioavailability
(Patel et al., 1984). Moreover, stability problems of HCT in
aqueous solution have been reported (Mollica et al., 1971)
At present, no liquid formulations of HCT are available on
the market. Extemporaneous liquid pediatric preparations are
generally obtained by suspending the drug powder in a suit-
able syrup (Atienza et al., 2011) or by grinding a fraction of
the commercial tablets and suspending it in a liquid vehicle
(Allen & Erickson, 2011). Attempts of developing stable low-
dosage HCT pediatric suspensions failed, due to problems of
variable drug recovery and limited stability (Santove~na
et al., 2012).
Lipid-based colloidal carriers proved to be an interesting
and successful strategy to enhance the stability and oral
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bioavailability of poorly soluble drugs. In particular, in recent
years, increasing attention has been paid towards the devel-
opment of the so-called solid lipid nanoparticles (SLNs),
which offer an effective alternative to the classic liposomes
or polymeric nanoparticles, overcoming some of their major
drawbacks, such as the low stability and poor loading cap-
acity of the first ones and the potential biotoxicity of the
second ones (M€uller et al., 2000; Mehnert & Mader, 2001;
Mukherjee et al., 2009)
SLNs are lipid matrix composed of biocompatible and bio-
degradable excipients able to protect the entrapped drug,
provide a controlled release and improve its bioavailability
(Silva et al., 2012; Gonc¸alves et al., 2016). We recently devel-
oped a low-dosage liquid HCT-loaded SLN formulation for
pediatric use (Cirri et al., 2017). In vivo studies on rats dem-
onstrated the enhanced therapeutic efficacy of such formula-
tion with respect to the simple drug aqueous suspension, in
terms of increased diuretic effect and prolonged release.
Nanostructured lipid carriers (NLCs) represent an evolution
of the original SLNs, containing a mixture of both solid and
liquid lipids. The use of spatially different lipids creates
imperfections in the crystal structure of the solid lipids, lead-
ing to various advantages compared to SLNs such as higher
entrapment efficiency, increased physical stability, less drug
expulsion during storage (Radtke & M€uller, 2001; M€uller
et al., 2002; Radtke et al., 2005; Muchow et al., 2008;
Severino et al., 2012; Beloqui, 2016).
Therefore, we considered it worthy of interest to investi-
gate the usefulness of employing NLC as a new carrier for
the oral administration of HCT in pediatric therapy, in order
to assess their actual advantages compared to SLNs, in terms
of drug entrapment efficiency, gastric and storage stabilities
and drug release properties. With this aim, the effect of dif-
ferent synthetic and natural liquid lipids and of two different
preparation methods, i.e. the homogenization-ultrasonication
(HU) and the microemulsion technique (ME) was evaluated
and compared in terms of particle size and homogeneity,
f-potential, entrapment efficiency, stability, and drug release
properties. Finally, the therapeutic efficacy of the best formu-
lations was evaluated in vivo on rat.
Materials and methods
2.1. Materials
Hydrochlorothiazide (HCT) was a generous gift of Menarini
(Italy). PrecirolVR ATO5 (Glyceryl distearate/palmitostearate),
TranscutolVR HP (highly purified diethylene glycol monoethyl
ether), LabrafacTM PG (propylene glycol dicaprylocaprate),
CapryolTM 90 (propylene glycol monocaprylate, type II),
LabrafilTM Lipophile WL1349 (medium-chain triglycerides)
and LabrasolVR (PEG-8 caprylic/capric glycerides) were kindly
provided by Gattefosse (Saint-Priest, France). Oleic acid, 1-
butanol, TweenVR 20 (polyoxyethylene sorbitan monolaurate)
and TweenVR 80 (polyoxyethylene sorbitan monoleate) were
from Merck (Darmstadt, Germany), castor and peanut oils
from Galeno (Prato, Italy), sesame oil from Farvima (Firenze,
Italy), sodium taurocholate from Prodotti Chimici e
Alimentari S.p.A. (Basaluzzo (AL), Italy), lecithin from Carlo
Erba Reagents (Milan, Italy), glycofurol (tetrahydrofurfury-
lether polyetylenglycol) and phosphatidylcholine from
Sigma-Aldrich (St. Louis, USA). SolutolVR HS15 (2-hydroxyethyl
12-hydroxyoctadecanoate) and PluronicVR F68 (Poloxamer 188)
were from BASF (Ludwigshafen, Germany). Purified water
was obtained by reverse osmosis (ElixVR Millipore, MD, USA).
All other chemicals were of analytical grade.
2.2. Vehicles screening
Selection of liquid lipids
PrecirolVR ATO5 was selected as solid lipid, based on previous
studies (Cirri et al., 2017). In order to select the most suitable
liquid lipid for drug-loaded NLC formulation, the solubilizing
power toward HCT of a series of synthetic (TranscutolVR HP,
CapryolTM 90, LabrafacTM PG, and LabrafilTM Lipophile
WL1349) and natural (oleic acid; castor, sesame, and peanut
oils) liquid lipids was tested. The HCT maximum amount
which can be dissolved in 5mL of each liquid lipid was
determined by adding stepwise, under stirring, increasing
HCT amounts (1–200mg) in the lipid thermostated at 65 C,
to mimic the experimental conditions needed for NLC pro-
duction, and allowed to equilibrate for 24 h. HCT solubility in
each system was evaluated by visual observation of dis-
appearance of drug crystals and formation of a transparent
homogeneous system (Nnamani et al., 2014).
Miscibility of solid and liquid lipid systems
The solid lipid PrecirolVR ATO5 was mixed with each liquid
lipid in the 90:10 w/w ratio, to evaluate the miscibility of the
two lipids. The mixtures were heated for 30min at 65 C and
then allowed to cool at room temperature. Any possible sign
of turbidity or phase separation process was assessed by vis-
ual inspection. Miscibility and solid state properties of cooled
samples were investigated also by Differential Scanning
Calorimetry (DSC). Analyses were performed with a Mettler
TA4000 Stare Software apparatus (Mettler Toledo,
Switzerland) equipped with a DSC 25 cell, by heating sam-
ples (5–10mg, Mettler MX5 microbalance, Mettler Toledo,
Switzerland) from 25 C to 100 C in pierced Al pans under
static air at a scan rate of 10 C min1. The instrument was
calibrated for temperature and heat flow using Indium as a
standard (99.98% purity; Tfus 156.61 C; DHfus 28.71 J g
1).
Selection of Co-Surfactants for microemulsions
PluronicVR F68 and TweenVR 80 were selected as surfactants,
based on previous studies (Cirri et al., 2017). Selection of Co-
Surfactants was performed by the titration method. Sodium
taurocholate, lecithin, and phosphatidylcholine were tested as
natural Co-Surfactants, and LabrasolVR , TranscutolVR , Glycofurol,
TweenVR 20 and SolutolVR HS15 as synthetic ones. Surfactant: Co-
Surfactant mixtures (at different w/w ratios) were added to a
fixed amount of a homogeneous and transparent solid: liquid
lipid mixture (90:10 w/w ratio) heated at 65 C. The resulting
mixtures were progressively titrated by adding water drop to
drop, under stirring, up to clouding. For each Co-Surfactant
able to form microemulsions, the % range in the existence
field of microemulsion was determined.
DRUG DELIVERY 1911
2.3. Preparation of NLC
NLCs were prepared according to two different methods, i.e.
HU (A), and ME (B).
A) According to the HU technique (Cirri et al., 2017), the
liquid lipid was added to the solid lipid PrecirolVR ATO5
melted at 65 C. The aqueous surfactant phase containing
PluronicVR F68 or TweenVR 80 heated at the same temperature
was added to the molten lipid phase and dispersed by a T25
digital ULTRA-TURRAX homogenizer (IKA Werke, Staufen,
Germany) at 10,000 rpm for 2min. The obtained pre-emul-
sion was then sonicated for 3min at 50% amplitude
(Sonopuls HD 2200 sonicator, Bandelin Electronics, Berlin,
Germany). Finally, the dispersion was cooled at 4 C to solid-
ify the lipid matrix and produce NLC. HCT-loaded NLC were
prepared by incorporating the drug (200mg) in the lipid
phase to obtain a drug concentration in the final dispersion
of 0.2% w/v.
B) According to the ME technique (Gasco, 1997), microe-
mulsions were prepared by melting the solid lipid at 65 C,
together with the liquid lipid followed by the addition of the
mixture Surfactant: Co-Surfactant under mechanical stirring;
water was later added in a concentration range within the
microemulsion existence field. The drug (200mg) was then
incorporated into the formed microemulsion. NLCs were
finally obtained by adding filtered warm water to the warm
microemulsion under mechanical stirring and then cooled at
4 C to allow lipid solidification.
All samples were stored at 4 C protected from light.
2.4. Characterization of NLC
Particle size, PDI and zeta potential
Physicochemical characterization of the lipid dispersions in
terms of mean particle size, polydispersity index (PDI) and
zeta potential was performed by Dynamic Light Scattering
(DLS), (Zetasizer Nano-ZS90, Malvern Instruments, Malvern,
UK). NLC dispersions were suitably diluted with bi-distilled
water before measurement, to avoid multi-scattering phe-
nomena. All measurements were carried out in triplicate
and results expressed as average values ± S.D.
Drug entrapment efficiency (EE%) and loading
capacity (LC%)
The percentage of HCT encapsulated into NLC and the load-
ing capacity were determined indirectly by the filtration/cen-
trifugation method (Cirri et al., 2012). Briefly, 1.5mL of NLC
dispersion were placed in the upper chamber of a mem-
brane concentrator (Vivaspin 2, 10,000 kDa MWCO, PSE,
Sartorius Stedim Biotech Ltd., G€ottingen, Germany) and cen-
trifuged for 8min at 4000 g (HERMLE Labortechnik, mod.
Z200A, Wehingen, Germany). The unentrapped drug col-
lected in the filtrate in the lower chamber was assayed by
UV spectroscopy (Shimadzu UV-1601) at 272.2 nm. The pres-
ence of lipids and other NLC components did not interfere
with the UV assay of the drug. Entrapment efficiency (% EE)
and Loading Capacity (% LC) were calculated according to
Equations (1) and (2), respectively:
EE% ¼ Winitial drug Wfree drug
Winitial drug
 100 (1)
LC% ¼ Winitial drug Wfree drug
Wlipid
 100 (2)
where “Winitial drug” is the initial drug amount used for NLC
preparation, “Wfree drug” the amount of free drug detected in
the filtrate and “Wlipid” the total amount of lipid used.
Results are expressed as average values ± S.D. of five sep-
arate experiments.
2.5. Stability studies
Stability studies of NLC under gastric conditions
The stability under gastric conditions of NLC was tested in
phosphate buffer at pH 4.5, selected as medium representing
the average gastric pH value typical of infant population
(Batchelor et al., 2013; Nguyen et al., 2015). Briefly, 1mL of
each NLC dispersion was put in 100mL of pH 4.5 phosphate
buffer and incubated at 37 C up to 2 h. Samples were tested
by DLS for particle size and PDI before and immediately after
their introduction in the gastric buffer (t0) and at the end of
the test (t2h). Determinations were performed in triplicate
and results expressed as mean values ± S.D.
Stability studies of NLC under storage
Stability studies of NLC were performed during 3months
storage at 4 C, by checking mean particle size, PDI and zeta
potential by DLS. Visual inspection was also employed to
detect any possible crystallization, precipitation, mold forma-
tion or gelling process. Determinations were performed in
triplicate and results expressed as average values ± S.D.
2.6. In vitro drug release studies
In vitro drug release studies from NLC were performed in
sink conditions according to the dialysis bag method (Cirri
et al., 2012, 2017) and compared to a simple drug suspen-
sion, prepared by suspending 0.2% p/v of HCT in water
under stirring. Cellulose acetate dialysis bags (Sigma-Aldrich,
St. Louis, MO,USA, 12,500 cut-off) were soaked overnight in
pH 4.5 gastric buffer, filled with 1mL of NLC dispersion or
suspension containing 2mg of drug and immersed for 2 h in
100mL of pH 4.5 phosphate buffer simulating the infant gas-
tric pH (drug solubility in the medium about 0.7mg/mL) and
then for 4 h in 100mL of pH 6.8 phosphate buffer (simulating
the intestinal pH), thermostated at 37 C and stirred at
50 rpm. The concentration of released drug was spectromet-
rically assayed at 272.2 nm at given time intervals. Each with-
drawn sample from the receiver solution was replaced with
an equal volume of fresh solvent. A correction for the cumu-
lative dilution was calculated. Experiments were performed
in triplicates and results expressed as mean values ± S.D.
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2.7. Statistical analysis
The results of all the above-described studies were statistic-
ally analyzed by one-way analysis of variance (ANOVA) fol-
lowed by the Student–Newman–Keuls multiple comparison
post-test using the Graph Pad Prism version 6.0 software
(San Diego, CA, USA). The differences were considered statis-
tically significant when p< .05.
Results of in vivo studies were expressed as mean
(±S.E.M.) and treated with the one-way ANOVA. A
Bonferroni’s significant difference procedure was used as a
post hoc comparison. p-values <.05 or <.01 were considered
significant. Data were analyzed using the Origin 9 software
(OriginLab, Northampton, MA, USA).
2.8. In vivo studies
For all the experiments described below, male
Sprague–Dawley rats (Envigo, Varese, Italy) weighing approxi-
mately 220–250 g at the beginning of the experimental pro-
cedure, were used. Animals were housed in CeSAL (Centro
Stabulazione Animali da Laboratorio, University of Florence)
and used at least one week after their arrival. Four rats were
housed per cage (size 26 41 cm); animals were fed a stand-
ard laboratory diet, tap water ad libitum, and kept at
23± 1 C with a 12 h light/dark cycle, light at 7 a.m. All ani-
mal manipulations were carried out according to the
Directive 2010/63/EU of the European Parliament and of the
European Union Council (22 September 2010) on the protec-
tion of animals used for scientific purposes. The ethical policy
of the University of Florence complies with the Guide for the
Care and Use of Laboratory Animals of the US National
Institutes of Health (NIH Publication No. 85–23, revised 1996;
University of Florence assurance number: A5278-01). Formal
approval to conduct the experiments described was obtained
from the Animal Subjects Review Board of the University of
Florence. Experiments involving animals have been reported
according to ARRIVE guidelines (McGrath & Lilley, 2015). All
efforts were made to minimize animal suffering and to
reduce the number of animals used.
Diuretic activity was determined according to the method
described by Olah et al. (2003) and Compaore et al. (2011),
slightly modified. Animals were divided into 4 groups (n¼ 5)
for the acute (single dose) study, with free access to food
and water. Before the treatment, all animals received physio-
logical saline (0.9% NaCl) as an oral dose of 2.5mL/100 g
body weight (Wiebelhaus et al., 1965) to impose a uniform
water and salt load, and kept at room temperature. One
hour later, rats were treated orally with a dose of 10mg kg
1 in the following manner: group I, serving as control, with
0.9% saline; group II with HCT suspension (0.2% p/v HCT in
water); groups III, IV and V with selected NLC formulations.
A further pharmacological study was performed on two
groups (n¼ 5), by treating one group with 0.9% saline (con-
trol) and the other one with empty nanoparticles, under the
same experimental conditions described above.
Immediately after administration, the animals were placed
in metabolic cages (one animal per cage), specially designed
to separate urine and feces, and cumulative urine output at
1, 2, 4, and 6 h was recorded. The diuretic activity was
expressed in mL/100 g body weight (Asif et al., 2014), while
the diuretic index was calculated as the ratio between the
diuresis of the animals treated with the test substance and
the diuresis of the control group (Danamma et al., 2011).
Results and discussion
3.1. Selection of liquid lipids
PrecirolVR ATO5 (5% w/w) was used as solid lipid for NLC prep-
aration and TweenVR 80 and PluronicVR F68 (1.5% w/w) as
Surfactants, since these components were formerly selected
in a previous study devoted to the development of HCT-
loaded SLNs (Cirri et al., 2017).
As a first step in the NLC formulation development, the
solubilizing capacity of a series of synthetic (TranscutolVR HP,
CapryolTM 90, LabrafacTMPG, LabrafilTM Lipophile WL1349)
and natural (oleic acid, castor, sesame, and peanut oils) liquid
lipids toward HCT was tested, in order to select the most
effective ones.
Among the examined synthetic liquid lipids,
TranscutolVR HP showed the highest solubilizing power, being
the only one able to dissolve up to 200mg of HCT in 5mL.
On the contrary, less than 80mg HCT were dissolved in 5mL
of CapryolTM 90, LabrafacTM PG and LabrafilTM Lipophile
WL1349. TranscutolVR HP was then selected as synthetic liquid
lipid for NLC formulation. On the other hand, natural oils
revealed a markedly lower solubilizing capacity compared to
synthetic lipids. Oleic acid and castor oil were able to dis-
solve 10 and 5mg of HCT in 5mL, respectively, whereas ses-
ame and peanuts oils solubilized only negligible amounts of
drug, lower than 3mg. Anyway, taking into account that the
NLC formulation we want to develop is intended for pediat-
ric patients, and natural oils generally being more tolerable
and biocompatible than the synthetic ones, we thought it
worthy of interest to consider both oleic acid and castor oil
for further studies, despite their lower solubilizing power
than TranscutolVR HP.
3.2. Miscibility of solid-liquid lipid systems
Miscibility of solid and liquid lipid at the specific concentra-
tions to be used in the formulation is a prerequisite for the
correct development of NLC formulations (Radtke & M€uller,
2001; M€uller et al., 2002; Radtke et al., 2005). The miscibility
between PrecirolVR ATO5 and the different liquid lipids was ini-
tially evaluated by both visual inspection upon heating and
DSC analysis in different w/w ratios: 99:1, 90:10, 80:20, and
70:30, according to the ratios most commonly used in litera-
ture (Pardeike et al., 2009).
Visual inspection allowed to rule out any sign of turbidity
or separation phase phenomena induced by cooling of the
heated mixtures, for each liquid lipid used.
DSC studies were performed to confirm the miscibility
between the selected liquid lipids and the solid lipid, based
on the lowering in its melting point which would be
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observed following incorporation of the liquid lipid in its
crystalline structure (Kasongo et al., 2011; Shah et al., 2016)
as well as to gain insight about the solid state properties of
PrecirolVR ATO5. The 90:10 w/w ratio was finally selected as
the best compromise since it allowed to have a relatively
high amount of liquid lipid, suitable to enhance the drug
solubility in the lipid phase, but, in the same time, to minim-
ize the toxicity risks.The obtained DSC curves for the binary
mixture 90:10 are shown in Fig. DSC as Supplementary data).
The thermal curve of pure PrecirolVR ATO5 before the heat-
ing process exhibited the presence of a single endothermic
effect with an onset and peak temperature at 50.9 C and
58.3 C, respectively, attributed to the melting of the stable
b–polymorphic form. However, following exposure for 30min
to 65 C and subsequent cooling at room temperature, the
DSC curve of the re-solidified lipid showed the appearance
of a shoulder, peaked at 48.3 C, before the major endother-
mic peak at 59 C, which may be attributed to the melting of
the metastable form a-, formed during the lipid recrystalliza-
tion (Saupe et al., 2005).
The decrease in onset, peak temperature and fusion
enthalpy of the endothermic peak of the PrecirolVR ATO5
b–form, exhibited by each examined binary mixture, corrobo-
rated the components miscibility, at least in the considered
90:10 w/w ratio. Moreover, all solid-liquid lipid combinations
showed a marked increase in the intensity of the endother-
mic effect at a lower temperature, observed in the DSC curve
of the re-solidified lipid and related to the presence of the
less crystalline a-form, and in the case of mixtures with
TranscutolVR HP this latter became even the major peak.
Therefore, it appears that the incorporation of the liquid lipid
into PrecirolVR ATO5 created defects within its highly ordered
crystalline structure, thus favoring the transformation from
the stable b- to the less ordered a-polymorphic form.
(Kasongo et al., 2011). Lipid matrices with some degree of
disorder are considered more suitable for formulation of
nanoparticulate lipid carriers, due to their greater active
ingredient payload capacity (M€uller, 2002; Attama et al.,
2006; Kasongo et al., 2011; Beloqui, 2016)
3.3. Characterization of NLC prepared by HU
The compositions of the different NLC formulations prepared
by HU employing PrecirolVR ATO5 as solid lipid, TweenVR 80 or
PluronicVR F68 as Surfactants, and three different liquid lipids
are reported in Table 1. NLC formulations were characterized
and compared in terms of mean particle size, PDI, zeta
potential (f), encapsulation efficiency (EE%) and loading cap-
acity (LC%) in order to investigate the influence of the type
of surfactant and liquid lipid. The results are collected in
Table 2.
The mean dimensions of all NLC formulations containing
PluronicVR F68 were smaller than those of the corresponding
ones with TweenVR 80, as found also by other authors (Padhye
& Nagarsenker, 2013; Bhupinder & Newton, 2016), and simi-
larly to what previously observed in the case of HCT-loaded
SLNs (Cirri et al., 2017).
Table 1. Composition of NLC formulations prepared with PrecirolVRATO5 as solid lipid, with TweenVR 80 (NLC1 serial code) or Pluronic
VR F68 (NLC2 serial code) as
Surfactant, and different liquid lipid (Transcutol (A), oleic acid (B) and castor oil (C)), both empty and loaded with hydrochlorothiazide (HCT).
Formulation
PrecirolVR ATO5
(%w/w)
Surfactant type (%w/w) Liquid lipid (%w/w)
Water (%w/w) HCT (mg)TweenV
R
80 PluronicV
R
F68 Transcutol Oleic acid Castor oil
NLC1A empty 5 1.5 – 0.55 – – 92.95 –
NLC1A 5 1.5 – 0.55 – – 92.95 200
NLC1B empty 5 1.5 – – 0.55 – 92.95
NLC1B 5 1.5 – – 0.55 – 92.95 200
NLC1C empty 5 1.5 – – – 0.55 92.95
NLC1C 5 1.5 – – – 0.55 92.95 200
NLC2A empty 5 – 1.5 0.55 – – 92.95
NLC2A 5 – 1.5 0.55 – – 92.95 200
NLC2B empty 5 – 1.5 – 0.55 – 92.95
NLC2B 5 – 1.5 – 0.55 – 92.95 200
NLC2C empty 5 – 1.5 – – 0.55 92.95
NLC2C 5 – 1.5 – – 0.55 92.95 200
Table 2. Mean particle size, polydispersity index (PDI), zeta potential (f), encapsulation efficiency (EE%) and loading capacity
(LC%) of different NLC formulations (see Table 1 for their composition).
Formulation size (nm) PDI f (mV) EE% LC%
NLC1A empty 571.3 ± 30.6 0.30 ± 0.02 25.2 ± 0.4 – –
NLC1A 605.6 ± 12.1 0.33 ± 0.05 29.0 ± 0.5 73.4 ± 2.4 2.9 ± 0.3
NLC2A empty 367.4 ± 2.8 0.29 ± 0.02 38.7 ± 0.9 – –
NLC2A 368.4 ± 7.6 0.24 ± 0.03 40.8 ± 0.3 53.9 ± 0.1 2.1 ± 0.1
NLC1B empty 483.6 ± 23.4 0.49 ± 0.03 35.0 ± 0.6 – –
NLC1B 650.6 ± 15.3 0.62 ± 0.13 37.6 ± 0.5 79.1 ± 0.6 3.2 ± 0.3
NLC2B empty –
a – – – –
NLC2B – – – – –
NLC1C empty 591.1 ± 22.0 0.42 ± 0.08 35.3 ± 0.8 – –
NLC1C 563.3 ± 3.7 0.36 ± 0.03 31.6 ± 1.6 80.0 ± 0.2 3.2 ± 0.0
NLC2C empty 365.1 ± 1.6 0.24 ± 0.04 42.4 ± 0.4 – –
NLC2C 405.4 ± 3.8 0.22 ± 0.02 38.8 ± 1.4 40.1 ± 3.2 1.6 ± 0.1
agelification occurred.
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This finding could be probably explained with a different
way of incorporation of the two surfactants in the particles
outer shell (Radomska-Soukharev, 2007).
Using oleic acid as liquid lipid and PluronicVR F68 as
Surfactant, it was not possible to obtain stable NLC disper-
sions, owing to gelling phenomena, which could be attrib-
uted to the building up by NLC particles of a sort of network
due to lipid bridges formation among them (Freitas & M€uller,
1998; Radomska-Soukharev, 2007). Such a finding may be
due to the different nature of oleic acid respect to the other
tested liquid lipids, being an unsaturated fatty acid.
PluronicVR F68 itself has a natural gelling tendency, that could
be accelerated by the presence of such a liquid lipid
(Morishita et al., 2001).
With the same liquid lipid and TweenVR 80 as Surfactant,
drug-loading led to a significantly higher PDI than the corre-
sponding empty formulation, exceeding 0.6, suggesting the
formation of a poorly uniform system, with great tendency
to aggregation phenomena. Therefore, such NLC formulation
was discarded.
Concerning NLC formulations containing TranscutolVR and
castor oil as liquid lipids, regardless of the kind of surfactant
used, the drug incorporation did not result in significant var-
iations (p< .05) in particle dimensions, PDI and zeta poten-
tial, thus indicating in all cases the formation of
homogeneous and stable nano-dispersions.
Regarding the EE%, the series of TweenVR 80-based NLC
(NLC1) showed significantly higher values than the corre-
sponding ones containing PluronicVR F68 (NLC2), irrespective
of the type of liquid lipid used. An analogous result was
observed for the loading capacity. In particular, the
TweenVR 80-based NLC containing castor oil as liquid lipid
showed the highest value of EE%, achieving 80%. Such a
value resulted clearly higher than that obtained in our previ-
ous study for the corresponding SLN formulations (Cirri et al.,
2017), and it can be reasonably attributed to the more disor-
dered solid lipid matrix of NLC than SLNs, making them
more available to incorporate more drug amounts.
3.4. Gastric stability studies
The gastric environment can negatively affect the stability of
NLC after their oral administration. In fact, the acid pH may
destabilize lipid carriers, leading to aggregation phenomena,
as a consequence of attractive forces, such as Van der Waals
and hydrophobic interactions (Paliwal et al., 2009; Das &
Chaudhury, 2011; Luo et al., 2015) and formation of micro-
particles, thus negatively influencing the drug release and
absorption properties of NLC (Zimmermann & M€uller, 2001;
Roger et al., 2009).
The gastric stability of NLC dispersions was studied in pH
4.5 buffer solution, selected as an average value for infant
population, their gastric pH being less acid than that of
adults, remaining in the 4–5 range after 2 h of feeding
(Batchelor et al., 2013; Nguyen et al., 2015).
The difficulty of reproducing the conditions of pediatric
patients in vitro makes the development of specific tests,
able to provide appropriate biopharmaceutics tools to
predict the in vivo performance of formulations aimed for
pediatric use, a very challenging task (Batchelor et al., 2014).
In this work, a lipolysis model was not used, due to the lack
of specific pediatric models. In fact, the various in vitro mod-
els designed for simulating the lipolysis processes in adults
are not suitable to reflect those occurring in infants, due to
the differences between adults and pediatric population. The
activity of digestive enzymes in the gastric and intestinal flu-
ids of the pediatric population has been widely investigated
(Zoppi et al., 1972; Hamosh et al., 1981; Hamosh et al., 1989;
Boehm, 1991; Di Palma et al., 1991; Armand et al., 1996;
Roman et al., 2007): in particular, concerning lipases, the
human gastric lipase (HGL) was found to play an important
role for the intragastric lipolysis in neonates (Moreau et al.,
1988; Bernback, 1990), as well as the carboxylester hydrolase
(CEH), also known as cholesterol ester lipase (CEL) and the
pancreatic lipase-related protein 2 (PLRP2) among the pan-
creatic lipases (Johnson et al., 2013). On the contrary, the
secretion of pancreatic triglyceride lipase (PTL) is lower in
neonates than in adults (Fredrikzon et al., 1988; Carriere
et al., 1993).
Kamstrup et al. (2017) suggested an in vitro model to
simulate the digestion process in the pediatric gastrointes-
tinal tract, starting from the original model developed by
Zangenberg et al (2001), providing general indications about
the most important physiological factors to be considered as
relevant such as media volume, pH and osmolality. However,
also these authors highlighted the difficulty and the com-
plexity of reproducing in vitro, the in vivo conditions, due to
both the lack of commercial availability of HGL and PLRP2
and the difficulties of estimating the levels of digest-
ive enzymes.
The gastric stability of the samples was investigated moni-
toring by DLS analysis potential changes in mean particle
size and PDI (as reported in Fig. gastric_stability_NLC as
Supplementary data). PluronicVR F68-based formulations (NLC2
series) showed aggregation phenomena immediately after
addition to the medium, followed by a further increase in
mean size during the incubation period. In particular, NLC2A,
containing TranscutolVR as liquid lipid showed a particle
growth up to a micrometric range, together with a drastic
increase in the PDI value, so this formulation was discarded.
On the contrary, in the presence of castor oil as liquid lipid
(NLC2C formulation), the particle size, even though increased,
remained in the nanometric range, and maintained a uniform
size distribution.
TweenVR 80-based formulations (NLC1 series), differently
from those containing PluronicVR F68, did not show any appre-
ciable change in the mean size, probably due to a more
effective steric stabilization effect of TweenVR 80, which can be
ascribed to the different adsorbing pattern on particles sur-
face exerted by the two different Surfactants (Reich, 1997;
Zimmermann & M€uller, 2001; Aditya et al., 2014; Luo et al.,
2015,). The higher stability of TweenVR 80-based systems com-
pared to PluronicVR F68 has been previously observed (Cirri
et al., 2017).
However, also for NLC1 series, dispersions with castor oil
(NLC1C) were more homogeneous than those with
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TranscutolVR (NLC1A), whose PDI rapidly increased, exceeding
values of 0.6, indicative of a not uniform nanoparticle
distribution.
Based on these results, only NLC formulations containing
castor oil as liquid lipid and TweenVR 80 or PluronicVR F68 as
surfactants (NLC1C and NLC2C), which showed satisfactory sta-
bility in gastric medium, were selected for release studies in
simulated gastrointestinal fluids.
3.5. In vitro release studies
The drug release curves obtained from the selected NLC for-
mulations prepared by HU (NLC1C and NLC2C) are shown in
Figure 1 together with that of the simple drug aqueous sus-
pension for comparison purpose. The drug suspension exhib-
ited a quite fast release rate in gastric medium achieving
nearly 40% drug released, being the fraction of drug in solu-
tion immediately ready to diffuse. Such a % value remained
almost constant during the next 4 h in pH 6.8 buffer. As pre-
viously observed for HCT-based SLNs (Cirri et al., 2017), the
type of surfactant clearly influenced the drug release profile.
For NLC containing PluronicVR F68 (NLC2C) a slowing down in
the drug release rate was observed, compared to the simple
drug suspension, achieving values only slightly higher than
20% drug released at the end of the text. On the contrary,
TweenVR 80-based NLC (NLC1C) showed a better drug release
profile with respect to the simple drug suspension, allowing
to achieve nearly 60% drug released. However, a complete
drug release was not achieved. Therefore, a new series of
NLC formulations were prepared, by using the ME method.
3.6. Preparation and characterization of microemulsion-
based NLC
A first screening aimed to select the Co-Surfactants able to
form microemulsions in the presence of a fixed amount of
PrecirolVR ATO5 and castor oil (90:10 w/w ratio) with each
Surfactant (PluronicVR F68 and TweenVR 80), was performed by
the titration method with water.
The amounts of Surfactant, solid and liquid lipid were
fixed at the same concentration as in the final NLC compos-
ition prepared by HU (NLC1C and NLC2C). A 1:1 w/w
Surfactant: Co-Surfactant (S:Co-S) ratio was initially used.
In the presence of TweenVR 80 as Surfactant, neither
sodium taurocholate nor lecithin, phosphatidylcholine or
LabrasolVR allowed microemulsions formation, whereas
TranscutolVR , Glycofurol, TweenVR 20 and SolutolVR HS gave rise
to clear empty microemulsions. However, the loading of the
drug was not possible with these Co-Surfactants, except for
SolutolVR HS which enabled obtainment of transparent drug-
loaded microemulsions when used in a % ranged between
11–17% w/w of the total microemulsion composition.
On the other hand, in the presence of PluronicVR F68 as
Surfactant, only TweenVR 20 and SolutolVR HS permitted the
formation of empty microemulsions, but none of them
allowed to obtain drug-loaded microemulsions.
Only a few of the tested S: Co-S combinations were suc-
cessful, since diluting with water and cooling lead to microe-
mulsion breakage, converting it into nanoemulsion, where
the formation of lipid particles occurred upon recrystalliza-
tion of the lipid phase. The nanoemulsion formation and the
lipid particle size are affected by several variables, including
the microemulsion composition (Chaturvedi & Kumar, 2012).
Figure 1. HCT in vitro release profiles from drug aqueous suspension or from TweenVR 80- and PluronicVR F68-based NLC formulations containing ricin oil as liquid
lipid (NLC1C and NLC2C) prepared by the homogenization-ultrasonication method.
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Therefore, we evaluated the possibility of extending the
number of Co-Surfactants able to form stable drug-loaded
microemulsions by increasing their content in the S:Co-S sys-
tems based on literature data about their safety and toxicity
(Food Safety Commission, 2007; Atthaporn et al., 2011;
Gopinathan et al., 2013; Sullivan et al., 2014). However,
among the Co-Surfactants resulted able to form empty
microemulsions, only Glycofurol and TweenVR 20 allowed their
use at 1:2 and 1:4 w/w S: Co-S ratios.
Nevertheless, Glycofurol was not able to form drug-loaded
microemulsions neither in 1:2 nor in 1:4 w/w S: Co-S ratios,
regardless of the type of Surfactant used.
On the contrary, TweenVR 20 permitted the obtainment of
drug-loaded microemulsions both in the 1:2 and 1:4 w/w
ratios if used, respectively, in the 22–28 and 33–44% range
of the total microemulsion composition, with PluronicVR F68 as
Surfactant, whereas only in the 1:4 w/w ratio with TweenVR 80,
if used in the 29–44% range.
Based on these results, a new series of NLC was prepared
starting by microemulsions containing S:Co-S mixtures of
TweenVR 80:TweenVR 20 at 1:4 w/w ratio (NLCI), Tween
VR 80:
SolutolVR HS at 1:1 w/w ratio (NLCII), Pluronic
VR F68:TweenVR 20 at
1:2 and 1:4 w/w ratios (NLCIII and NLCIV).
The microemulsion: water v/v ratio was varied, depending
on the % of Co-Surfactant used, in order to keep the final
concentration of solid and liquid lipid and Surfactant con-
stant (5%, 0.55%, and 1.5%, respectively).
The obtained systems were characterized in terms of par-
ticle size, PDI, zeta potential, encapsulation efficiency and
loading capacity (Table 3).
The PluronicVR F68-based microemulsions did not give rise
to stable NLC formation; in fact, both kinds of dispersed sys-
tems (NLCIII and NLCIV) showed particle size values in the
micrometric range, with very high PDI values. On the con-
trary, in the presence of TweenVR 80, both with TweenVR 20
(NLCI) and Solutol
VR HS (NLCII) as Co-Surfactants, stable NLC
were obtained with particle size values around 330 and
430 nm, respectively, which resulted smaller than those of
NLC obtained with the HU method with the same Surfactant.
Furthermore, NLC prepared by the ME technique exhib-
ited higher EE% values than the corresponding TweenVR 80-
based NLC produced by the HU method, allowing to achieve
values ranging from 86% with SolutolVR HS up to 93% with
TweenVR 20 (vs 80% obtained with the HU method). These
EE% values were also clearly higher than those obtained
with the best SLN formulation (57.5%) (Cirri et al., 2017).
Table 3. Mean particle size, polydispersity index (PDI), zeta potential (f), Encapsulation Efficiency (EE%) and Loading Capacity (LC%) of different ME-based NLC
formulations.
Code S:Co-S (w/w ratio) size (nm) PDI f (mV) EE% LC%
NLCI Tween
VR 80:TweenVR 20 327.6 ± 3.7 0.38 ± 0.03 25.1 ± 0.3 93.2 ± 0.5 3.7 ± 0.2
1:4
NLCII Tween
VR 80:SolutolV
R
HS 429.3 ± 11.2 0.39 ± 0.02 25.0 ± 0.9 86.0 ± 0.3 3.4 ± 0.2
1:1
NLCIII Pluronic
VR F68:TweenVR 20 >1lm 1 – – –
1:2
NLCIV Pluronic
VR F68:TweenV
R
20 >1lm 1 – – –
1:4
Figure 2. HCT in vitro release profiles from NLC formulations produced by the microemulsion method containing S:Co-S mixtures of TweenVR 80:TweenVR 20 at 1:4
w/w ratio (NLCI) and TweenVR 80:SolutolVR HS at 1:1 w/w ratio (NLCII) in comparison with the corresponding Tween
VR 80-based NLC formulations prepared by the hom-
ogenization-ultrasonication method (NLC1C) and simple aqueous suspension.
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Both NLCI and NLCII formulations were stable in pH 4.5
gastric buffer, without showing any significant change in
mean size and PDI both after addition to the medium and
during the incubation period (see Fig. gastric_stability_NLC-
ME reported as Supplementary data).
In vitro release studies (Figure. 2) revealed a prolonged
release, which lasted for 6 h from both the formulations,
higher not only than the simple HCT aqueous suspension
but also than the corresponding NLC prepared with the HU
method (NLC1C). NLCII achieved 80% drug released at the
end of the test.
Moreover, NLCI showed in absolute the best performance,
giving rise to a complete drug release within 6 h,
never achieved with the previous SLN formulations
Figure 3. Diuretic effect expressed in terms of: volume of excreted urine (mL) (A); diuretic activity (ml/100g body weight) (B) and diuretic index (C) after oral
administration (drug dose of 10mg kg1) of the selected HCT-loaded NLCI, NLCII and NLC1C formulations.
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(Cirri et al., 2017). Such a finding confirmed the microemul-
sion technique as the most effective method to produce
HCT-loaded NLC formulations.
3.7. In vivo studies
The diuretic effect in terms of volume of excreted urine, diur-
etic activity, and diuretic index after oral administration of
the selected HCT-loaded NLCI, NLCII, and NLC1C formulations
(all at the drug dose of 10mg kg1) was evaluated in normal
adult male rats and compared with the effect induced by
oral administration of the same dose of HCT as aqueous sus-
pension (Figure 3 (A–C)). As can be observed in Figure 3(A),
HCT suspension, acutely administered, significantly increased
the diuresis from 1h up to 6 h after treatment in comparison
to the control group treated with saline (4.8 ± 0.5ml,
10.3 ± 0.5ml vs 1.8 ± 0.6ml, 6.0 ± 1.2ml). All the tested NLC
formulations were able to significantly increase the urinary
outflow up to 6 h after administration in comparison to the
control group. However, treatments with NLC1C showed a
urinary output comparable to that evoked by HCT suspen-
sion. An appreciable improvement in the excreted urine vol-
ume after 4 and 6 h was instead for observed in the case of
NLCII. A further increment of the urine volume was obtained
with NLCI formulation, which displayed the better diuretic
profile, significantly (p< .05) superior than that of HCT sus-
pension at 4 h–6 h after treatment.
The diuretic activity, expressed as ml/100g body weight,
highlighted similar results to those above described (Figure 3
(B)). All compounds were able to increase the diuretic activity
up to 6 h after treatment in comparison to the control group,
showing an analogous trend of efficacy: NLCI>NLCII>NLC1C
 HCT, further confirming the better efficacy of
NLCI treatment.
At last, the diuretic index was calculated as the ratio
between the diuresis of the animals treated with the test
compound compared to the diuresis of the control group
(Figure 3C). Also, in this case, NLCI was the most effective
formulation, exhibiting the highest diuretic index at 4 h and
6h than all the others treated group.
The further pharmacological study performed on rats
treated with empty NLC demonstrated that the components
of the nanoparticles have no effect on diuresis, compared to
the control, showing similar values (p  .05) of both volumes
of excreted urine and diuretic activity, leading to a diuretic
index equal to 1.
Therefore, we can conclude that in vivo studies demon-
strated that the HCT formulation as NLCI led to a superior
therapeutic efficacy in terms of increased intensity of the
diuretic effect with respect to the simple aqueous drug sus-
pension attributable to an enhancement of drug bioavailabil-
ity. Moreover, an extension of the duration of action can be
reasonably assumed, based on the sustained release proper-
ties exhibited by the developed NLCI formulation.
In order to better highlight the overall effect of each
treatment, the AUC values (the area under the urine volume
curve versus time) obtained by each drug treatment were
calculated. Their comparison confirmed the increased
bioavailability of HCT when administered as NLC prepared
with the microemulsion method: in particular, the most
important enhancement of the oral bioavailability was
observed for NLCI formulation, whose AUC values resulted
almost 20% higher than that of the corresponding
drug suspension.
3.8. Stability studies of stored NLC
Stability studies of the selected NLC formulations, stored at
4 C, were carried out over 3months and the results
expressed in terms of mean particle size, PDI and
zeta potential.
A moderate reduction of the particle size was registered
for all formulations during the storage period. Such a trend
had been already observed in a previous work (Cirri et al.,
2017) and attributed to some loss of lipid (Radomska-
Soukharev, 2007), depending on the type of Surfactant, that
can lead to a different incorporation in the nanoparticles sur-
face, or to a different solubilization capacity for water in the
lipid phase, thus differently affecting the lipid matrix chem-
ical stability (Radomska-Soukharev & M€uller, 2006).
NLC1C formulation was found to be stable up to 2months,
since the marked increase in the PDI observed after this time
(over 0.6) could indicate a polydisperse system with a ten-
dency to aggregation. On the contrary, in the case of ME-
based NLC, no important variations of PDI values (estimated
about 0.4 for freshly prepared NLC) were observed for all
NLC series during the considered storage period of three
months. Both NLCI and NLCII showed zeta potential values
lower than 30mV but sufficient to obtain stable dispersions
due to the presence of a sterically stabilizing surfactant
(Radomska-Soukharev, 2007).
HCT-loaded NLC prepared by the ME method resulted sta-
ble for a longer time than the corresponding previous SLNs
(Cirri et al., 2017), thus evidencing the advantage of NLC
compared to SLNs also in terms of improved stor-
age stability.
Conclusions
In this study, new low-dosage liquid oral formulations of HCT
were developed, by using NLC as carrier delivery system.
The study highlighted the importance of the proper
choice of the NLC components and of the preparation
method on their performance. A different influence of the
preparation method on both the technological and release
properties of NLC as well as on their stability was also
pointed out. The ME technique proved to be the most effect-
ive method to produce HCT-loaded lipid formulations, giving
rise to advantages in terms of smaller particle size (ranging
from about 300 and 400 nm for NLCI and NLCII obtained by
microemulsion, vs more than 500 nm for NLC1C) and
increased entrapment efficiency, allowing to achieve value of
93% and 86% EE, respectively. Such values resulted higher
not only compared to NLC obtained by HU method but also
to the previously prepared SLNs (57.5%). (Cirri et al., 2017).
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In particular, NLCI was the best formulation, assuring a
complete and sustained drug release up to 6h (never
achieved with the previous SLN formulations (Cirri et al.,
2017), that resulted in an improved therapeutic efficacy of
this formulation in terms of increased diuretic effect, when
orally administered in rats, compared to the simple aqueous
drug suspension.
Finally, all the HCT-loaded NLC formulations prepared by
the ME method showed stability over three months, higher
than the previous corresponding SLN formulations (Cirri
et al., 2017).
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